GSK and CureVac Restructuring Existing Collaboration into New Licensing Agreement

DENVER, Colo., Jul 03, 2024 ( GSK plc (NYSE:GSK) and CureVac N.V. (Nasdaq:CVAC) stated that they are restructured their existing collaboration into a new licensing agreement, which allows each company to prioritize investment and focus their respective mRNA development activities.

GSK and CureVac have worked together to develop mRNA vaccines, since 2020, and, under the terms of the new agreement, GSK will assume full control of developing and manufacturing these candidate vaccines. GSK will have worldwide rights to commercialize the candidate vaccines, while CureVac will receive an upfront payment of €400 million and up to an additional €1.05 billion in development, regulatory and sales milestones and tiered royalties in the high single to low teens range.

GSK’s Chief Scientific Officer, Tony Wood, stated, “We are excited about our flu/COVID-19 programs and the opportunity to develop best-in-class mRNA vaccines to change the standard of care. With this new agreement, we will apply GSK’s capabilities, partnerships and intellectual property to CureVac’s technology, to deliver these promising vaccines at pace.”

CureVac’s CEO, Alexander Zehnder, commented, “The collaboration with GSK has been instrumental in developing promising, late clinical-stage vaccine candidates, leveraging our proprietary mRNA platform. This new licensing agreement puts us in a strong financial position and enables us to focus on efforts in building a strong R&D pipeline.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to for disclaimer information.

24/7 Market News
[email protected]

Related news for (NYSE:GSK) ( Nasdaq:CVAC)

    NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.